Using artificial intelligence to improve treatment for rectal cancer in veterans
Official title: Artificial Intelligence Imaging Predictors for Rectal Cancer Management
Funded at Louis Stokes Cleveland VA Medical Center · NIH-10807273 · Data updated 2026-11-12
This study is looking at how artificial intelligence can create personalized treatment plans for veterans with rectal cancer, helping to find the best therapies for each individual, especially older veterans with other health issues, to improve their treatment results and overall well-being.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| NIH project number | 1I01BX006439-01 |
| Project ID | NIH-10807273 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are veterans diagnosed with rectal cancer, particularly those who are older and may have additional health issues.
✕Less likely to help
Patients who do not have rectal cancer or are not veterans may not receive any benefit from this research.
What this research studies
This research investigates how artificial intelligence can help personalize treatment plans for veterans diagnosed with rectal cancer. By analyzing imaging data, the study aims to identify which patients are likely to benefit from specific therapies, such as neoadjuvant chemotherapy and surgery. The goal is to move away from a one-size-fits-all approach to a more tailored strategy that considers individual patient characteristics, particularly for older veterans with additional health concerns. This could lead to better treatment outcomes and quality of life for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for veterans with rectal cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promising results using artificial intelligence in cancer treatment personalization, indicating potential for success in this approach.
Where this research is happening
-
Louis Stokes Cleveland VA Medical Center
Cleveland, United States Active
Researchers
- Principal investigator: Viswanath, Satish Easwar — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Viswanath, Satish Easwar
Related research
Other NIH-funded projects on the same topics.
-
Molecular Characterization of Radiation Effects in Rectal Cancer
A patient-facing platform study aims to link tissue changes, imaging, and the immune system during radiotherapy for rectal cancer to improve future treatments.
-
Immune System and Radiation in Rectal Cancer
This grant supports a small international study to understand how radiation therapy interacts with the immune system in rectal cancer by collecting tumor, blood, stool, and lymph node samples from patients before and after treatment.
-
Targeting tryptophan metabolism to improve rectal cancer treatment
This NIH grant is exploring a new way to help people with locally advanced rectal cancer by combining radiation with a drug that blocks a pathway our immune system uses to protect tumors.
-
Time-restricted eating during rectal cancer treatment to reduce toxicity and improve outcomes
A clinical trial tests whether eating only within a set time window during cancer treatment can reduce side effects and help treatments work better for rectal cancer patients.
-
Enhancing Rectal Cancer Immunotherapy with Radiation-Induced Senescence and PTPN2 Inhibition
This grant explores a combo approach using radiation and a targeted inhibitor to boost the body's immune attack on rectal cancer, aiming to preserve the organ and reduce long-term side effects.
-
Early response to radiotherapy and immunotherapy in rectal cancer
A new approach combines short-course radiation, chemotherapy, and an immune therapy antibody to try to shrink rectal cancers before surgery or avoid surgery altogether.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.